© 2006 Foundation for Promotion of Cancer Research
Editorial |
Adjuvant Therapy in Rectal Cancer: What is the Truth?
Internal Medicine II, Osaka Medical College, Takatsuki, Osaka, Japan
For reprints and all correspondence: Hiroya Takiuchi, Internal Medicine II, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka, 569-8686, Japan. E-mail: in2028@poh.osaka-med.ac.jp
| The first 10% of the full text of this article appears below. |
It's just like déjà vu. Japanese surgeons have often been dismissive of the value of adjuvant treatment for gastric cancer reported from Europe and America (1,2) because of differences in the degree of lymph node dissection between Japan and Europe/America (3). In contrast, Japanese surgeons may be surprised and delighted at the results of the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC) of postoperative adjuvant chemotherapy for rectal cancer published in this issue of the JJCO (4), the results of which have not been so exciting for European and American oncologists. Such